Postradiation Malignant Fibrous Histiocytoma and Osteosarcoma of a Patient with High Telomerase Activities

TOSHIHIRO MATSUO1, TAKASHI SUGITA2, SHOJI SHIMOSE1, TADAHIKO KUBO1, YUJI YASUNAGA1, EISO HIYAMA3 and MITSUO OCHI1

1Department of Orthopaedic Surgery and 3Natural Science Center for Basic Research and Development, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima; 2Department of Orthopaedic Surgery, Hiroshima Prefectural Hospital, Hiroshima, Japan

Abstract. Background: An extremely rare case of postradiation malignant fibrous histiocytoma (MFH) and osteosarcoma (OS) secondary to radiation therapy for leukemia-related osteolytic lesions is presented. In addition, the telomere biology of these tumors was investigated. Case Report: A 14-year-old boy was diagnosed with acute lymphocytic leukemia. The right tibia was irradiated at a total dose of 60 Gy, and the left tibia was irradiated at a total dose of 40 Gy. The left tibia developed MFH and the right tibia developed OS. Results: Telomere reduction (MFH 70.2, OS 70.0%) and high telomerase activities (MFH 12.1, OS 17.7 TPG) were observed. These results reflect an aggressive feature of postradiation sarcomas. Conclusion: Prognosis for patients diagnosed with postradiation sarcoma is poor due to its aggressiveness. However, even if sarcoma occurs after irradiation in more than two fields in a single patient, improvements in prognosis are anticipated with appropriate chemotherapies and wide resection.

The incidence of postradiation of bone sarcoma is very low, being estimated to occur in less than 1% of irradiated patients, but postradiation sarcoma is a serious, long-term complication of radiation therapy (1, 2). Here, the first case of postradiation malignant fibrous histiocytoma (MFH) and osteosarcoma (OS), which developed in the bilateral proximal tibia in the same patient, following radiation therapy for leukemia-related osteolytic lesions, is reported. In addition, the telomere biology of these tumors was investigated for parameters of aggressiveness.

Correspondence to: Toshihiro Matsuo, MD, Ph.D., Department of Orthopaedic Surgery, Graduate School of Biomedical Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8551, Japan. Tel: +81-82-257-5233, Fax: +81-82-257-5234, e-mail: tmatsu@hiroshima-u.ac.jp

Key Words: Postradiation sarcoma, malignant fibrous histiocytoma, osteosarcoma, telomerase activity, telomere length.
Figure 1. T1-weighted sagittal MRI (TR 516/TE 12) demonstrates a non-homogeneous large mass of low signal intensity protruding from the left tibia.

Figure 2. Malignant fibrous histiocytoma of giant cell type. The presence of numerous multinucleated giant cells is accompanied by hemorrhagic necrosis (x200).

Figure 3. T1-weighted coronal MRI (TR 466/TE 9) demonstrates a non-homogeneous mass of low signal intensity protruding from the right tibia.

Figure 4. Osteosarcoma of osteoblastic type. Spindle tumor cells with strong heteromorphism exhibit hyperplasia. (x200).
right proximal tibia revealed abnormal findings (Figure 3). An open biopsy was performed and a pathological diagnosis of osteosarcoma (osteoblastic type) was confirmed (Figure 4). CBDCA (100 mg/m²), VP-16 (100 mg/m²) and MTX (10~12 g/m²) were administered for a total of four courses as neoadjuvant chemotherapy. In July 2003, wide resection of the sarcoma and reconstruction with prosthesis were performed. For postoperative chemotherapy, CBDCA (100 mg/m²), VP-16 (100 mg/m²) and MTX (12 g/m²) were administered in a total of six courses from August to December 2003 and, as of January 2005, no local recurrence or metastasis has been observed.

Materials and Methods

Tissue samples. Tumor samples were obtained from the patient by resection, and normal muscle samples were also obtained as healthy tissue samples under informed consent. After surgery, all samples were immediately frozen and stored at −80°C until use.

Telomere length analysis by Southern blotting. Genomic DNA was isolated from frozen samples of tumor and paired normal muscles. For the analysis of telomere length, 2 μg of DNA were digested to completion with 10 units of Hinf 1, electrophoresed on 0.8% agarose gels and then blotted onto nitrocellulose filters. The filters were hybridized to a 32P-labelled (TTAGGG)₄ probe, washed and then autoradiographed. The mean length of TRFs was estimated at peak position of hybridization signal using the Bioimage Analyzer (BAS 2000, FUJIFILM, Tokyo, Japan) and MacBass software (FUJIFILM).

Telomerase assay. Evaluation of telomerase activity was performed by the TRAP (telomeric repeat amplification protocol) assay. Briefly, frozen tumors and adjacent normal muscle samples of 50-100 mg were homogenized in 200 μl of CHAPS lysis buffer. After 25 minutes of incubation on ice, the lysates were centrifuged at 16,000 x g for 20 minutes at 4°C, and the supernatant was frozen at −80°C. The concentration of tumor protein was measured using the BCA Protein Assay Kit (Pierce Chemical Co., Rockford, IL, USA), and an aliquot containing 1 μg of tumor protein was used for each TRAP assay. The levels of telomerase activity were measured using the TRAPEze XL Telomerase Detection Kit (Intergen Co., NY, USA), which is a quantitative fluorescein-labelled PCR system, with the use of a PCR internal control. For the direct detection of fluorescein and sulphorhodamine, the PCR product was measured in a fluorescent plate reader to detect the levels of fluorescein and sulphorhodamine by using the appropriate excitation and emission filters. The telomerase activity was quantified by the ratio of the fluorescein intensity of the entire TRAP ladder to the sulphorhodamine intensity of the internal control after the correction of each fluorescent intensity for the negative control and the background, and was expressed as Total Product Generated (TPG) units.

Results

The telomere length of the two adjacent normal muscles was 12.4 kb and 12.0 kb, whereas those of the postradiation tumors were 8.7 kb (MFH) and 8.4 kb (OS) (Figure 5). The telomere lengths of the tumors were shorter than those of normal tissues (percentage of telomere reduction; MFH 70.2%, OS 70.0%). Telomerase activity was detectable in tumor samples, with detectable levels of 12.1 TPG (MFH) and 17.7 TPG (OS).

Discussion

Successful management of malignant neoplasms can be achieved by combinations of therapies such as irradiation, chemotherapy and surgery. On the other hand, the risk of secondary cancer is increased by the use of such methods to improve cancer patient prognosis. Postradiation sarcoma is a rare type of iatrogenic cancer (3). Amendola et al. estimated an incidence of 0.09-0.11% among cases after radiation therapy (4) and Tountas et al. reported that postradiation sarcoma of bone occurred in 0.02% of irradiated patients (5). Postradiation sarcoma is sometimes misdiagnosed because it is rare and, thus, it is necessary for clinicians to remain vigilant for this disease following radiotherapy (6).

Radiation-induced sarcomas reportedly require high doses of radiation (3, 7). There are several reports
indicating that the sarcoma is generated by irradiation of 40 Gy or more, with no appearance of sarcoma after doses of 30 Gy or less. Tountas et al. reported a secondary osteosarcoma after treating a primary malignant neoplasm with 40 to 70 Gy (5), and Murray et al. reported that no postradiation sarcoma patient received less than 30 Gy (8). Our patient received irradiation at 40 Gy and 60 Gy in the left and right tibia and, thus, our observations are in agreement with these reports.

Some reports have suggested that higher doses of radiotherapy are associated with a shorter latency (9,10). In contrast, other reports were inconclusive regarding the relationship between latency and dose (1). In the present case, the latency period was shorter by four years after 40-Gy irradiation than after 60-Gy irradiation. This contradicts the notion that larger doses of radiation result in shorter periods of time before developing sarcoma. Furthermore, in the present patient, MFH took eight years and seven months and OS took twelve years and eight months to develop after the start of the radiotherapy. Hence, there was an approximately four-year difference in the latent period. According to previous reports, there is no clear difference in the latent periods between MFH and OS (3, 9).

If treatment of cancer does not necessarily require radiotherapy, irradiation should be avoided wherever possible. However, prognosis in many cancer patients is improved by radiotherapy. For patients who have undergone irradiation, regular observation of the irradiated area is necessary. If pain, swelling and/or local heat develop in an irradiated area, postradiation sarcoma should be considered and the area should be subjected to MRI scanning.

The chemotherapeutic agents used in the treatment of cancer have been shown to be oncogenic in animals (11), and it is evident that many of these agents increase the expected damage to tissue when given in conjunction with radiotherapy. The risk of radiation-induced sarcoma increases with the use of high-dose chemotherapy, and the latent period to secondary tumors becomes shorter in cases treated with combined therapy (12, 13). The present patient had leukemia as the underlying disease and required potent chemotherapy. Therefore, it is also necessary to consider the likelihood of postradiation sarcoma when radiotherapy is performed on patients with underlying diseases requiring chemotherapy.

Many telomere-related studies have been conducted on human carcinomas for diagnostic and/or prognostic value. Telomerase activity has been reported in 80-90% of carcinomas, and in some types of carcinomas high telomerase activity has been cited as a marker of tumor aggressiveness (14-18). In addition, a considerable shortening of telomeres has been found in many cancer cells, despite the expression of telomerase (15-18, 19). In contrast, almost no benign tumors express telomerase activity (19). Postradiation sarcoma is a very aggressive tumor and the prognosis for patients is generally poor (9, 10). In our study, telomere reduction was observed in tumor samples and high telomerase activity was detected. These results reflect the aggressive nature of postradiation sarcomas. Treatment for secondary sarcomas is based on surgical resection and additional therapies, such as chemotherapy, may also be necessary. In the present case, no metastasis or local recurrence was observed, probably due to early diagnosis, chemotherapy and wide resection.

An extremely rare case of postradiation malignant fibrous histiocytoma and osteosarcoma occurring in the bilateral tibia of the same patient, following secondary radiation therapy for leukemia-related osteolytic lesions, with telomere reductions and high telomerase activities, was reported here. It is necessary to consider the occurrence of postradiation sarcoma when irradiation of 40 Gy or more is used. In addition, even when the exposure dose is relatively small, sarcoma may exhibit short latencies and, thus, long-term observation of all irradiated fields is necessary. However, even if sarcoma occurs after irradiation in more than two fields in a single patient, improvements in prognosis are anticipated by appropriate chemotherapies and wide resection.

References


Received February 17, 2005
Accepted May 17, 2005